



Drug Formulary Update, January 2021 Commercial Programs

Updates to the HealthPartners Commercial Formularies (PreferredRx and GenericsAdvantageRx) are listed below.

Please see www.healthpartners.com/formularies for details.

Updates are effective January 1, 2021.

Drug name	Current Status	New Status	Comments
Apomorphine (Kynmobi)		NF-PA	A new FDA-approval.
Azacitidine (Onureg)	NF	F-PA-QL-SP	Added with standard oncology PA.
Budesonide ER (Ortikos)		NF-PA	A new FDA-approval.
Budesonide/ glycopyrrolate/ formoterol inhaler (Breztri)		NF-PA	A new FDA-approval.
Cannabidiol (Epidiolex)	F-SP-PA-QL	F-SP-PA-QL	PA coverage criteria have been updated.
Carbidopa	F	NF*	Preferred alternatives include levodopa/ carbidopa. * PreferredRx-only. GenericsAdvantageRx will be updated April 1 2021.
Decitabine/ cedazuridine (Inqovi)		F-SP-PA-QL	A new FDA-approval.
Desloratadine	NF-PA*	NF	* GenericsAdvantageRx-only. Both formularies have the same NF status.
Diphtheria, pertussis, tetanus, polio vaccine (Quadracel)	NF	F	
Diroximel fumarate (Vumerity)	F-PA-QL-SP*	F-QL-SP	* GenericsAdvantageRx-only. Both formularies have the same F-QL-SP status.
Doxycycline DR	NF-PA	NF-PA	PA update. Preferred alternatives include doxycycline monohydrate 50mg and 100mg capsules.
Elagolix/ estradiol/ norethindrone (Oriahnn)		F-PA-QL-SP	A new FDA-approval.

Drug name	Current Status	New Status	Comments
Emtricitabine solution (Emtriva)	F	NF*	Emtricitabine capsules are preferred. * PreferredRx-only. GenericsAdvantageRx will be updated April 1 2021.
Fenfluramine (Fintepla)		F-SP-PA	A new FDA-approval
Fostemsavir (Rukobia)		F-PA	A new FDA-approval.
Hepatitis A vaccine (Vaqta)	NF	F	
Hepatitis B vaccine (Recombivax)	NF	F	
Icosapent ethyl (Vascepa)	F-PA	F-PA	PA coverage criteria have been updated.
Insulin degludec (Tresiba)	NF-PA	NF-PA	PA coverage criteria have been updated.
Insulin detemir (Levemir)	F-PA	F-PA	PA coverage criteria have been updated.
Insulin glargine (Basaglar)	NF-PA	NF-PA	PA coverage criteria have been updated.
Insulin glargine (Semglee)		NF-PA	A new FDA-approval.
Insulin lispro (Admelog)	NF-PA	NF-PA	PA coverage criteria have been updated.
Insulin lispro (Lyumjev)		NF-PA	A new FDA-approval.
Lactic acid/ citric acid/ potassium bitartrate vaginal gel (Phexxi)		NF-PA*	A new FDA-approval. * PreferredRx-only. GenericsAdvantageRx will be updated from NF on April 1 2021.
Levocetirizine	NF-PA*	NF	* GenericsAdvantageRx-only. Both formularies have the same NF status.
Levonorgestrel/ ethinyl estradiol patch (Twirla)		NF-PA	A new FDA-approval.
Measles, mumps, and rubella vaccine (M-M-R II)	NF	F	
Meningococcal vaccine (Menveo)	NF	F	
Minocycline ER	NF-PA	NF-PA	PA coverage criteria have been updated. Preferred alternatives include minocycline 50mg and 100mg capsules.
Minocycline foam (Amzeeq)	NF-PA	NF-PA	PA coverage criteria have been updated.
Minocycline foam (Zilxi)	NF-PA	NF-PA	PA coverage criteria have been updated.
Monomethyl fumarate (Bafiertam)		F-QL-SP	A new FDA-approval.
Octreotide capsule (Mycapssa)		NF-PA-SP	A new FDA-approval.
Octreotide pen (Bynfezia)		F-PA-SP	A new FDA-approval.
Ofatumumab (Kesimpta)		F-QL-SP	A new FDA-approval
Opicapone (Ongentys)		NF-PA	A new FDA-approval.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, SP = Specialty Drug, QL = Quantity Limit

Drug name	Current Status	New Status	Comments
Osilodrostat (Isturisa)	NF-PA-SP	NF-PA-SP	PA coverage criteria have been updated.
Oxymetazoline eye drop (Upneeq)		NF-PA	A new FDA-approval.
Ozanimod (Zeposia)		F-QL-SP	A new FDA-approval.
Poliomyelitis vaccine (Ipol)	NF	F	
Risdiplam (Evrysdi)		F-PA-SP	A new FDA-approval
Rotavirus vaccine (Rotarix and Rotateq)	NF	F	
Satralizumab (Enspryng)		F-PA-SP	A new FDA approval
Sulfacetamide/ sulfur suspension 8-4%	NF	NF-PA*	Adding PA. Preferred alternatives include sulfacetamide/ sulfur 10-5%. * PreferredRx-only. GenericsAdvantageRx will be updated April 1 2021.
Sumatriptan nasal spray (Tosymra)	NF-QL*	NF-PA-QL	* PreferredRx-only. Both formularies will have the same NF-PA-QL status.
Tecovirimat (Tpoxx)		F-PA	A new FDA-approval.
Tetanus and diphtheria (Tenivac)	NF	F	
Tolvaptan (Jynarque)	NF-SP-PA	NF-SP-PA	PA coverage criteria have been updated.
Triheptanoin (Dojolvi)		F-PA-SP	A new FDA-approval.